The 2NN study - CD8 T cells

More documents

Recommendations

Info

% patie nts with virologic success 100 75 50 25 0 Virologic success by baseline pVL overall baseline pVL < 5log 10 baseline pVL > 5log 10 65.0 51.5 63.6 53.7 67.8 61.3 61.7 57.1 71.1 68.2 71.1 64.0 NVP-od NVP-bd EFV NVP+EFV Frank van Leth 10
percentage of patients 100 75 50 25 0 pVL < 50 copies/mL ITT * p=0.193 0 2 4 8 12 18 24 36 48 weeks after start allocated treatment NVP-od NVP-bd Frank van Leth 11 EFV NVP+EFV NVP-od n=220 70.0 % NVP-bd n=387 65.4 % EFV n=400 70.0 % NV P + EFV n=209 62.7 % *
Page 1 and 2: The 2NN study A randomised comparat
Page 3 and 4: NVP 400 mg od n=220 Trial design 12
Page 5 and 6: Methods • All analyses Intention-
Page 7 and 8: Baseline characteristics NVP-od NVP
Page 9: % patie nts with virologic success
Page 13 and 14: number of CD4+ -cells (median (IQR)
Page 15 and 16: Grade 3 or 4 laboratory toxicities
Page 17 and 18: plasma HDL mmol/L 1.50 1.25 1.00 0.
Page 19 and 20: Conclusions • NVP and EFV have co
Page 21 and 22: Acknowledgements (2) Other investig

The 2NN study - CD8 T cells

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?